JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy

  • 0From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Pancreas +

|

July 10, 2024

|

July 10, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Lower metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET scans predict longer progression-free survival (PFS) in metastatic neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT).

Area Of Science

  • Oncology
  • Nuclear Medicine
  • Radiology

Background

  • Metastatic neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors.
  • Peptide receptor radionuclide therapy (PRRT) is a standard treatment for advanced NENs.
  • Predictive biomarkers for PRRT response are crucial for personalized treatment strategies.

Purpose Of The Study

  • To evaluate metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from pre-treatment FDG-PET scans as prognostic markers.
  • To assess the association of MTV and TLG with overall survival (OS) and progression-free survival (PFS) in metastatic NEN patients undergoing PRRT.

Main Methods

  • Retrospective analysis of 105 metastatic NEN patients treated with PRRT.
  • Pre-treatment FDG-PET imaging was used to quantify MTV and TLG.
  • Patients were stratified into high vs. low MTV/TLG groups based on median values.
  • OS and PFS were compared between the high and low MTV/TLG groups.

Main Results

  • Lower MTV/TLG was significantly associated with longer PFS (21.6 months vs. 45.7 months; P = 0.007).
  • No significant difference in OS was observed between high and low MTV/TLG groups (47.4 months vs. not reached; P = 0.0594).
  • MTV and TLG dichotomization resulted in identical patient cohorts.

Conclusions

  • Pre-treatment FDG-PET-derived MTV and TLG are valuable prognostic indicators for PFS in metastatic NEN patients receiving PRRT.
  • Low MTV/TLG suggests a favorable prognosis regarding disease progression after PRRT.
  • These imaging biomarkers may aid in treatment selection and patient counseling.